Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and often dose-limiting complication of cancer therapy utilizing taxanes, platinum-based drugs and newer agents such as bortezomib. Currently, no clearly effective therapies exist for prevention or treatment of CIPN. This proposal focuses on preclinical investigation of vitamin D deficiency, as a potential risk factor for paclitaxel-associated painful CIPN.